Literature DB >> 34275040

Is Splenic Hilar Lymph Node Dissection Without Splenectomy Essential for Proximal Advanced Gastric Cancer?

Yoon Jung Oh1, Deok Hee Kim1, Bang Wool Eom1, Hong Man Yoon1, Young-Woo Kim1, Keun Won Ryu2.   

Abstract

BACKGROUND: The standard surgery for proximal advanced gastric cancer (PAGC) is total gastrectomy with D2 lymph node dissection (LND). Although prophylactic splenectomy for splenic hilar LND (No. 10) is not recommended due to any survival advantage, prophylactic LND (No. 10) without splenectomy remains controversial. Thus, we aimed to evaluate whether No. 10 LND is essential for patients' survival benefit in PAGC.
METHODS: We conducted a retrospective study of 1038 patients with PAGC who underwent total gastrectomy without splenectomy. After adjusting for confounders and propensity score matching (PSM), patients were grouped into Group 1 (D2 LND without splenic hilar LN; n = 288) or Group 2 (D2 LND with splenic hilar LN; n = 288). Variables between the two groups (5-year overall survival [OS] and disease-free survival [DFS]) were compared, as well as in patients with tumors located in the greater curvature and those with Borrmann type IV disease.
RESULTS: The 5-year OS and DFS rates after PSM were not significantly different between Groups 1 and 2 (57.3% vs. 62.1%, p = 0.300; 52.8% vs. 59.7%, p = 0.100, respectively). Furthermore, the 5-year OS and DFS rates in patients with greater curvature involvement (54.4% vs. 61.9%, p = 0.500; 50.0% vs. 57.6%, p = 0.400, respectively) and Borrmann type IV disease (23.8% vs. 38.6%, p = 0.400; 16.7% vs. 33.9%, p = 0.200, respectively) after PSM were also not significantly different between the two groups.
CONCLUSIONS: Prophylactic splenic hilar LND without splenectomy does not improve long-term survival in PAGC. Therefore, this procedure might not be essential for patients with PAGC as well greater curvature involvement and Borrmann type IV disease.
© 2021. Society of Surgical Oncology.

Entities:  

Year:  2021        PMID: 34275040     DOI: 10.1245/s10434-021-10354-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  17 in total

1.  Laparoscopic spleen-preserving splenic hilar lymph node dissection during total gastrectomy for gastric cancer.

Authors:  Woo Jin Hyung; Joon-Seok Lim; Jyewon Song; Seung Ho Choi; Sung Hoon Noh
Journal:  J Am Coll Surg       Date:  2008-08       Impact factor: 6.113

2.  The Therapeutic Survival Benefit of Splenic Hilar Nodal Dissection for Advanced Proximal Gastric Cancer Invading the Greater Curvature.

Authors:  Masahiro Yura; Takaki Yoshikawa; Sho Otsuki; Yukinori Yamagata; Shinji Morita; Hitoshi Katai; Toshirou Nishida
Journal:  Ann Surg Oncol       Date:  2018-12-19       Impact factor: 5.344

3.  Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer.

Authors:  W Yu; G S Choi; H Y Chung
Journal:  Br J Surg       Date:  2006-05       Impact factor: 6.939

4.  Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer.

Authors:  Seok-Ki Kim; Keon Wook Kang; Jong Seok Lee; Hark Kyun Kim; Hee Jin Chang; Jin Yi Choi; Jun Ho Lee; Keun Won Ryu; Young-Woo Kim; Jae-Moon Bae
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-15       Impact factor: 9.236

5.  Impact of splenectomy in patients with gastric adenocarcinoma of the cardia.

Authors:  Chikara Kunisaki; Hirochika Makino; Hirokazu Suwa; Tsutomu Sato; Takashi Oshima; Yasuhiko Nagano; Syoichi Fujii; Hirotoshi Akiyama; Masato Nomura; Yuichi Otsuka; Hidetaka A Ono; Takashi Kosaka; Ryo Takagawa; Yasushi Ichikawa; Hiroshi Shimada
Journal:  J Gastrointest Surg       Date:  2007-08       Impact factor: 3.452

6.  Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma.

Authors:  Takeshi Sano; Mitsuru Sasako; Junki Mizusawa; Seiichiro Yamamoto; Hitoshi Katai; Takaki Yoshikawa; Atsushi Nashimoto; Seiji Ito; Masahide Kaji; Hiroshi Imamura; Norimasa Fukushima; Kazumasa Fujitani
Journal:  Ann Surg       Date:  2017-02       Impact factor: 12.969

7.  The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer.

Authors:  Sung Jin Oh; Woo Jin Hyung; Chen Li; Jyewon Song; Wookho Kang; Sun Young Rha; Hyun Cheol Chung; Seung Ho Choi; Sung Hoon Noh
Journal:  J Surg Oncol       Date:  2009-04-01       Impact factor: 3.454

8.  Clinical significance of splenic hilar lymph node metastasis in proximal gastric cancer.

Authors:  Suk Hee Shin; Hun Jung; Seong Hee Choi; Ji Yeong An; Min Gew Choi; Jae Hyung Noh; Tae Sung Sohn; Jae Moon Bae; Sung Kim
Journal:  Ann Surg Oncol       Date:  2009-02-25       Impact factor: 5.344

9.  Total gastrectomy with simultaneous pancreaticosplenectomy or splenectomy in patients with advanced gastric carcinoma.

Authors:  E Otsuji; T Yamaguchi; K Sawai; K Okamoto; T Takahashi
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

10.  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Authors:  Daniel Dindo; Nicolas Demartines; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

View more
  2 in total

1.  Can a single-port robot be safely used for robotic total gastrectomy for advanced gastric cancer? First experience using the da Vinci SP platform.

Authors:  Hao Cui; Jian-Xin Cui; Ke-Cheng Zhang; Wen-Quan Liang; Shu-Yan Li; Jun Huang; Lin Chen; Bo Wei
Journal:  Gastroenterol Rep (Oxf)       Date:  2022-06-07

2.  Efficacy of the No. 10 lymphadenectomy with spleen preservation on patients with gastric cancer and/or esophagogastric junction adenocarcinoma who underwent total gastrectomy: a systematic review and meta-analysis.

Authors:  Bo-Wei Xia; Chen Wang; Yong-Yong Liu; Yong Fan; Xiao-Dong He; Ying-Xin Kang; Xin-Yuan Zhou; Xiao-Lu Su; Yue-Bin Wang; Min-Xue Chen; Bo-Xiong Kang
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.